Colorectal Cancer

The Shield blood-based CRC screening test demonstrated a sensitivity of 84% for detecting CRC with 90% specificity in an expanded cohort.

Sharlene Gill, BScPharm, MD, MPH, MBA, FRCPC, discusses the rationale for evaluating patient experiences and involvement in CRC treatment decision-making.

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Cathy Eng, MD, FACP, FASCO, discusses the clinical significance of a real-world study of KRAS G12C mutations on treatment outcomes in mCRC.

The MMR IHC Panel pharmDx was certified in the EU as a companion diagnostic to identify patients with colorectal cancer eligible for nivolumab/ipilimumab.

Evelyn Y.T. Wong, MD, discusses discussed the potential use of molecular characteristics to predict survival outcomes in early-onset CRC.

Benjamin L. Schlecter, MD, discusses the potential next steps in research for botensilimab for the treatment of patients with metastatic colorectal cancer.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

The FDA granted breakthrough device designation to the Haystack MRD ctDNA liquid biopsy for stage II colorectal cancer.

D3S-001 has received FDA breakthrough therapy and orphan drug designations in KRAS G12C-mutated NSCLC and CRC, respectively.

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

Connie Lai, MD, discusses an analysis of post-induction maintenance vs treatment break in metastatic colorectal cancer.

John L. Marshall, MD, discusses the use of fruquintinib in the treatment of patients with metastatic colorectal cancer.

John Marshall, MD, discusses fruquintinib’s efficacy in later-line CRC, advocating for the agent’s use as maintenance therapy to avoid overtreatment.

The FDA has approved the MMR IHC Panel pharmDx to determine eligibility for nivolumab/ipilimumab in patients with MSI-H/dMMR colorectal cancer.

Magrolimab plus nivolumab and FOLFOX with bevacizumab or cetuximab yielded responses in advanced/recurrent colorectal cancer.

Rocío García-Carbonero, MD, discusses fruquintinib for the treatment of patients with metastatic colorectal cancer.

Tanios S. Bekaii-Saab, MD, discusses sequencing approaches in metastatic pancreatic cancer and colorectal cancer.

Fulzerasib monotherapy was safe and active in KRAS G12C–mutated metastatic colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses efforts to shift emerging targeted therapies into earlier treatment lines for patients with mCRC.

Botensilimab plus balstilimab displayed durable responses in refractory CRC, including in heavily pretreated patient subsets.

Evelyn Y. Wong, MD, discusses an analysis of a multiracial Asian cohort on the incidence of early‑onset colorectal cancer.

Evelyn Y.T. Wong, MD, discusses survival outcomes and molecular characteristics of patients with early-onset colorectal cancer from a cohort in Singapore.